Global Human Immumoglobulin (PH4) for Intravenous Injection Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Human Immumoglobulin (PH4) for Intravenous Injection market size was valued at US$ 12871 million in 2025 and is forecast to a readjusted size of US$ 22252 million by 2032 with a CAGR of 8.1% during review period.
In 2025, global Human Immumoglobulin (PH4) for Intravenous Injection production reached approximately 150.3 tons, with an average global market price of around 83.2 USD/g.
Human Immunoglobulin (PH4) for Intravenous Injection is a sterile blood product derived from pooled plasma of healthy donors, with a pH value maintained at 3.8-4.4 to ensure biological activity. It contains over 95% IgG antibodies, undergoes virus inactivation and removal processes, and serves dual roles of immune replacement and immune regulation. Clinically, it is mainly indicated for primary immunoglobulin deficiencies (e.g., X-linked agammaglobulinemia), secondary deficiencies (e.g., severe infections, neonatal sepsis), and autoimmune diseases (e.g., idiopathic thrombocytopenic purpura, Kawasaki disease). It is a prescription-only biological product requiring strict quality control and regulatory approval.
Driven by aging populations, rising prevalence of autoimmune diseases, expanded clinical indications, and post-pandemic emphasis on immunotherapy, global demand for Human Immunoglobulin (PH4) for Intravenous Injection remains robust, often facing supply shortages due to plasma source constraints. Business opportunities lie in optimizing plasma collection networks to boost raw material supply, advancing production technologies (e.g., nanofiltration, low-pH incubation) for improved yield and safety, developing high-concentration or specialty formulations to meet personalized treatment needs, exploring emerging markets with growing healthcare access, and leveraging policy support for biopharmaceuticals to expand market penetration and enhance product accessibility through pricing and reimbursement strategies.
This report is a detailed and comprehensive analysis for global Human Immumoglobulin (PH4) for Intravenous Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Concentration and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Human Immumoglobulin (PH4) for Intravenous Injection market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/g), 2021-2032
Global Human Immumoglobulin (PH4) for Intravenous Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/g), 2021-2032
Global Human Immumoglobulin (PH4) for Intravenous Injection market size and forecasts, by Concentration and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/g), 2021-2032
Global Human Immumoglobulin (PH4) for Intravenous Injection market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/g), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Human Immumoglobulin (PH4) for Intravenous Injection market is split by Concentration and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Concentration, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Concentration
Chapter 1, to describe Human Immumoglobulin (PH4) for Intravenous Injection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Immumoglobulin (PH4) for Intravenous Injection, with price, sales quantity, revenue, and global market share of Human Immumoglobulin (PH4) for Intravenous Injection from 2021 to 2026.
Chapter 3, the Human Immumoglobulin (PH4) for Intravenous Injection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Immumoglobulin (PH4) for Intravenous Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Concentration and by Application, with sales market share and growth rate by Concentration, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Human Immumoglobulin (PH4) for Intravenous Injection market forecast, by regions, by Concentration, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Immumoglobulin (PH4) for Intravenous Injection.
Chapter 14 and 15, to describe Human Immumoglobulin (PH4) for Intravenous Injection sales channel, distributors, customers, research findings and conclusion.
In 2025, global Human Immumoglobulin (PH4) for Intravenous Injection production reached approximately 150.3 tons, with an average global market price of around 83.2 USD/g.
Human Immunoglobulin (PH4) for Intravenous Injection is a sterile blood product derived from pooled plasma of healthy donors, with a pH value maintained at 3.8-4.4 to ensure biological activity. It contains over 95% IgG antibodies, undergoes virus inactivation and removal processes, and serves dual roles of immune replacement and immune regulation. Clinically, it is mainly indicated for primary immunoglobulin deficiencies (e.g., X-linked agammaglobulinemia), secondary deficiencies (e.g., severe infections, neonatal sepsis), and autoimmune diseases (e.g., idiopathic thrombocytopenic purpura, Kawasaki disease). It is a prescription-only biological product requiring strict quality control and regulatory approval.
Driven by aging populations, rising prevalence of autoimmune diseases, expanded clinical indications, and post-pandemic emphasis on immunotherapy, global demand for Human Immunoglobulin (PH4) for Intravenous Injection remains robust, often facing supply shortages due to plasma source constraints. Business opportunities lie in optimizing plasma collection networks to boost raw material supply, advancing production technologies (e.g., nanofiltration, low-pH incubation) for improved yield and safety, developing high-concentration or specialty formulations to meet personalized treatment needs, exploring emerging markets with growing healthcare access, and leveraging policy support for biopharmaceuticals to expand market penetration and enhance product accessibility through pricing and reimbursement strategies.
This report is a detailed and comprehensive analysis for global Human Immumoglobulin (PH4) for Intravenous Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Concentration and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Human Immumoglobulin (PH4) for Intravenous Injection market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/g), 2021-2032
Global Human Immumoglobulin (PH4) for Intravenous Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/g), 2021-2032
Global Human Immumoglobulin (PH4) for Intravenous Injection market size and forecasts, by Concentration and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/g), 2021-2032
Global Human Immumoglobulin (PH4) for Intravenous Injection market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/g), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Human Immumoglobulin (PH4) for Intravenous Injection market is split by Concentration and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Concentration, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Concentration
- 5%
- 10%
- 20%
- Standard-Qualified Plasma
- High-Safety Plasma
- Special-Indication
- Cohn-Fractionation
- Chromatography-Purified
- Ultrafiltration-Refined
- Immunodeficiency Disease
- Autoimmune Disease
- Severe Infectious Disease
- Boya-Bio
- Beijing Tiantan Biological Products
- Guangdong Shuagnlin Bio-pharmacy
- Weiguang Biological
- Hualan Bio
- CTBB
- Sinopharm
- Nanyue Biopharming
- Shanghai RAAS
- ADMA Biologics
- Grand Shuyang
- PAFC
- Weiguang Biological Products
- Beijing Bohui Innovation Biotechnology
- CSL Behring
- Takeda
- Grifols
- Octapharma
- Bio Products Laboratory
- Kedrion
- LFB
- GC Biopharma
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Human Immumoglobulin (PH4) for Intravenous Injection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Immumoglobulin (PH4) for Intravenous Injection, with price, sales quantity, revenue, and global market share of Human Immumoglobulin (PH4) for Intravenous Injection from 2021 to 2026.
Chapter 3, the Human Immumoglobulin (PH4) for Intravenous Injection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Immumoglobulin (PH4) for Intravenous Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Concentration and by Application, with sales market share and growth rate by Concentration, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Human Immumoglobulin (PH4) for Intravenous Injection market forecast, by regions, by Concentration, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Immumoglobulin (PH4) for Intravenous Injection.
Chapter 14 and 15, to describe Human Immumoglobulin (PH4) for Intravenous Injection sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Concentration
1.3.1 Overview: Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Concentration: 2021 Versus 2025 Versus 2032
1.3.2 5%
1.3.3 10%
1.3.4 20%
1.4 Market Analysis by Source Plasma Screening Standard
1.4.1 Overview: Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Source Plasma Screening Standard: 2021 Versus 2025 Versus 2032
1.4.2 Standard-Qualified Plasma
1.4.3 High-Safety Plasma
1.4.4 Special-Indication
1.5 Market Analysis by Production Process
1.5.1 Overview: Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Production Process: 2021 Versus 2025 Versus 2032
1.5.2 Cohn-Fractionation
1.5.3 Chromatography-Purified
1.5.4 Ultrafiltration-Refined
1.6 Market Analysis by Application
1.6.1 Overview: Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Immunodeficiency Disease
1.6.3 Autoimmune Disease
1.6.4 Severe Infectious Disease
1.7 Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size & Forecast
1.7.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (2021-2032)
1.7.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Boya-Bio
2.1.1 Boya-Bio Details
2.1.2 Boya-Bio Major Business
2.1.3 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.1.4 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Boya-Bio Recent Developments/Updates
2.2 Beijing Tiantan Biological Products
2.2.1 Beijing Tiantan Biological Products Details
2.2.2 Beijing Tiantan Biological Products Major Business
2.2.3 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.2.4 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Beijing Tiantan Biological Products Recent Developments/Updates
2.3 Guangdong Shuagnlin Bio-pharmacy
2.3.1 Guangdong Shuagnlin Bio-pharmacy Details
2.3.2 Guangdong Shuagnlin Bio-pharmacy Major Business
2.3.3 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.3.4 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates
2.4 Weiguang Biological
2.4.1 Weiguang Biological Details
2.4.2 Weiguang Biological Major Business
2.4.3 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.4.4 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Weiguang Biological Recent Developments/Updates
2.5 Hualan Bio
2.5.1 Hualan Bio Details
2.5.2 Hualan Bio Major Business
2.5.3 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.5.4 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Hualan Bio Recent Developments/Updates
2.6 CTBB
2.6.1 CTBB Details
2.6.2 CTBB Major Business
2.6.3 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.6.4 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 CTBB Recent Developments/Updates
2.7 Sinopharm
2.7.1 Sinopharm Details
2.7.2 Sinopharm Major Business
2.7.3 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.7.4 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Sinopharm Recent Developments/Updates
2.8 Nanyue Biopharming
2.8.1 Nanyue Biopharming Details
2.8.2 Nanyue Biopharming Major Business
2.8.3 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.8.4 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Nanyue Biopharming Recent Developments/Updates
2.9 Shanghai RAAS
2.9.1 Shanghai RAAS Details
2.9.2 Shanghai RAAS Major Business
2.9.3 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.9.4 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Shanghai RAAS Recent Developments/Updates
2.10 ADMA Biologics
2.10.1 ADMA Biologics Details
2.10.2 ADMA Biologics Major Business
2.10.3 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.10.4 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 ADMA Biologics Recent Developments/Updates
2.11 Grand Shuyang
2.11.1 Grand Shuyang Details
2.11.2 Grand Shuyang Major Business
2.11.3 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.11.4 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Grand Shuyang Recent Developments/Updates
2.12 PAFC
2.12.1 PAFC Details
2.12.2 PAFC Major Business
2.12.3 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.12.4 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 PAFC Recent Developments/Updates
2.13 Weiguang Biological Products
2.13.1 Weiguang Biological Products Details
2.13.2 Weiguang Biological Products Major Business
2.13.3 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.13.4 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Weiguang Biological Products Recent Developments/Updates
2.14 Beijing Bohui Innovation Biotechnology
2.14.1 Beijing Bohui Innovation Biotechnology Details
2.14.2 Beijing Bohui Innovation Biotechnology Major Business
2.14.3 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.14.4 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Beijing Bohui Innovation Biotechnology Recent Developments/Updates
2.15 CSL Behring
2.15.1 CSL Behring Details
2.15.2 CSL Behring Major Business
2.15.3 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.15.4 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 CSL Behring Recent Developments/Updates
2.16 Takeda
2.16.1 Takeda Details
2.16.2 Takeda Major Business
2.16.3 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.16.4 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Takeda Recent Developments/Updates
2.17 Grifols
2.17.1 Grifols Details
2.17.2 Grifols Major Business
2.17.3 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.17.4 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Grifols Recent Developments/Updates
2.18 Octapharma
2.18.1 Octapharma Details
2.18.2 Octapharma Major Business
2.18.3 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.18.4 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Octapharma Recent Developments/Updates
2.19 Bio Products Laboratory
2.19.1 Bio Products Laboratory Details
2.19.2 Bio Products Laboratory Major Business
2.19.3 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.19.4 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 Bio Products Laboratory Recent Developments/Updates
2.20 Kedrion
2.20.1 Kedrion Details
2.20.2 Kedrion Major Business
2.20.3 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.20.4 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 Kedrion Recent Developments/Updates
2.21 LFB
2.21.1 LFB Details
2.21.2 LFB Major Business
2.21.3 LFB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.21.4 LFB Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.21.5 LFB Recent Developments/Updates
2.22 GC Biopharma
2.22.1 GC Biopharma Details
2.22.2 GC Biopharma Major Business
2.22.3 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.22.4 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.22.5 GC Biopharma Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION BY MANUFACTURER
3.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Manufacturer (2021-2026)
3.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Manufacturer (2021-2026)
3.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Human Immumoglobulin (PH4) for Intravenous Injection by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Human Immumoglobulin (PH4) for Intravenous Injection Manufacturer Market Share in 2025
3.4.3 Top 6 Human Immumoglobulin (PH4) for Intravenous Injection Manufacturer Market Share in 2025
3.5 Human Immumoglobulin (PH4) for Intravenous Injection Market: Overall Company Footprint Analysis
3.5.1 Human Immumoglobulin (PH4) for Intravenous Injection Market: Region Footprint
3.5.2 Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Type Footprint
3.5.3 Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Region
4.1.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Region (2021-2032)
4.1.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2021-2032)
4.1.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2021-2032)
4.2 North America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032)
4.3 Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032)
4.4 Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032)
4.5 South America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032)
4.6 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032)
5 MARKET SEGMENT BY CONCENTRATION
5.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2032)
5.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Concentration (2021-2032)
5.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2032)
6.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Application (2021-2032)
6.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2032)
7.2 North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2032)
7.3 North America Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country
7.3.1 North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2032)
7.3.2 North America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2032)
8.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2032)
8.3 Europe Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country
8.3.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2032)
8.3.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2032)
9.2 Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Region
9.3.1 Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2032)
10.2 South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2032)
10.3 South America Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country
10.3.1 South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2032)
10.3.2 South America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2032)
11.2 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country
11.3.1 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
12.2 Human Immumoglobulin (PH4) for Intravenous Injection Market Restraints
12.3 Human Immumoglobulin (PH4) for Intravenous Injection Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Human Immumoglobulin (PH4) for Intravenous Injection and Key Manufacturers
13.2 Manufacturing Costs Percentage of Human Immumoglobulin (PH4) for Intravenous Injection
13.3 Human Immumoglobulin (PH4) for Intravenous Injection Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Human Immumoglobulin (PH4) for Intravenous Injection Typical Distributors
14.3 Human Immumoglobulin (PH4) for Intravenous Injection Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Concentration
1.3.1 Overview: Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Concentration: 2021 Versus 2025 Versus 2032
1.3.2 5%
1.3.3 10%
1.3.4 20%
1.4 Market Analysis by Source Plasma Screening Standard
1.4.1 Overview: Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Source Plasma Screening Standard: 2021 Versus 2025 Versus 2032
1.4.2 Standard-Qualified Plasma
1.4.3 High-Safety Plasma
1.4.4 Special-Indication
1.5 Market Analysis by Production Process
1.5.1 Overview: Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Production Process: 2021 Versus 2025 Versus 2032
1.5.2 Cohn-Fractionation
1.5.3 Chromatography-Purified
1.5.4 Ultrafiltration-Refined
1.6 Market Analysis by Application
1.6.1 Overview: Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Immunodeficiency Disease
1.6.3 Autoimmune Disease
1.6.4 Severe Infectious Disease
1.7 Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size & Forecast
1.7.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (2021-2032)
1.7.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Boya-Bio
2.1.1 Boya-Bio Details
2.1.2 Boya-Bio Major Business
2.1.3 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.1.4 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Boya-Bio Recent Developments/Updates
2.2 Beijing Tiantan Biological Products
2.2.1 Beijing Tiantan Biological Products Details
2.2.2 Beijing Tiantan Biological Products Major Business
2.2.3 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.2.4 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Beijing Tiantan Biological Products Recent Developments/Updates
2.3 Guangdong Shuagnlin Bio-pharmacy
2.3.1 Guangdong Shuagnlin Bio-pharmacy Details
2.3.2 Guangdong Shuagnlin Bio-pharmacy Major Business
2.3.3 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.3.4 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates
2.4 Weiguang Biological
2.4.1 Weiguang Biological Details
2.4.2 Weiguang Biological Major Business
2.4.3 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.4.4 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Weiguang Biological Recent Developments/Updates
2.5 Hualan Bio
2.5.1 Hualan Bio Details
2.5.2 Hualan Bio Major Business
2.5.3 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.5.4 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Hualan Bio Recent Developments/Updates
2.6 CTBB
2.6.1 CTBB Details
2.6.2 CTBB Major Business
2.6.3 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.6.4 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 CTBB Recent Developments/Updates
2.7 Sinopharm
2.7.1 Sinopharm Details
2.7.2 Sinopharm Major Business
2.7.3 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.7.4 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Sinopharm Recent Developments/Updates
2.8 Nanyue Biopharming
2.8.1 Nanyue Biopharming Details
2.8.2 Nanyue Biopharming Major Business
2.8.3 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.8.4 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Nanyue Biopharming Recent Developments/Updates
2.9 Shanghai RAAS
2.9.1 Shanghai RAAS Details
2.9.2 Shanghai RAAS Major Business
2.9.3 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.9.4 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Shanghai RAAS Recent Developments/Updates
2.10 ADMA Biologics
2.10.1 ADMA Biologics Details
2.10.2 ADMA Biologics Major Business
2.10.3 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.10.4 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 ADMA Biologics Recent Developments/Updates
2.11 Grand Shuyang
2.11.1 Grand Shuyang Details
2.11.2 Grand Shuyang Major Business
2.11.3 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.11.4 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Grand Shuyang Recent Developments/Updates
2.12 PAFC
2.12.1 PAFC Details
2.12.2 PAFC Major Business
2.12.3 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.12.4 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 PAFC Recent Developments/Updates
2.13 Weiguang Biological Products
2.13.1 Weiguang Biological Products Details
2.13.2 Weiguang Biological Products Major Business
2.13.3 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.13.4 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Weiguang Biological Products Recent Developments/Updates
2.14 Beijing Bohui Innovation Biotechnology
2.14.1 Beijing Bohui Innovation Biotechnology Details
2.14.2 Beijing Bohui Innovation Biotechnology Major Business
2.14.3 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.14.4 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Beijing Bohui Innovation Biotechnology Recent Developments/Updates
2.15 CSL Behring
2.15.1 CSL Behring Details
2.15.2 CSL Behring Major Business
2.15.3 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.15.4 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 CSL Behring Recent Developments/Updates
2.16 Takeda
2.16.1 Takeda Details
2.16.2 Takeda Major Business
2.16.3 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.16.4 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Takeda Recent Developments/Updates
2.17 Grifols
2.17.1 Grifols Details
2.17.2 Grifols Major Business
2.17.3 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.17.4 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Grifols Recent Developments/Updates
2.18 Octapharma
2.18.1 Octapharma Details
2.18.2 Octapharma Major Business
2.18.3 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.18.4 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Octapharma Recent Developments/Updates
2.19 Bio Products Laboratory
2.19.1 Bio Products Laboratory Details
2.19.2 Bio Products Laboratory Major Business
2.19.3 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.19.4 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 Bio Products Laboratory Recent Developments/Updates
2.20 Kedrion
2.20.1 Kedrion Details
2.20.2 Kedrion Major Business
2.20.3 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.20.4 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 Kedrion Recent Developments/Updates
2.21 LFB
2.21.1 LFB Details
2.21.2 LFB Major Business
2.21.3 LFB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.21.4 LFB Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.21.5 LFB Recent Developments/Updates
2.22 GC Biopharma
2.22.1 GC Biopharma Details
2.22.2 GC Biopharma Major Business
2.22.3 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
2.22.4 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.22.5 GC Biopharma Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION BY MANUFACTURER
3.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Manufacturer (2021-2026)
3.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Manufacturer (2021-2026)
3.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Human Immumoglobulin (PH4) for Intravenous Injection by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Human Immumoglobulin (PH4) for Intravenous Injection Manufacturer Market Share in 2025
3.4.3 Top 6 Human Immumoglobulin (PH4) for Intravenous Injection Manufacturer Market Share in 2025
3.5 Human Immumoglobulin (PH4) for Intravenous Injection Market: Overall Company Footprint Analysis
3.5.1 Human Immumoglobulin (PH4) for Intravenous Injection Market: Region Footprint
3.5.2 Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Type Footprint
3.5.3 Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Region
4.1.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Region (2021-2032)
4.1.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2021-2032)
4.1.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2021-2032)
4.2 North America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032)
4.3 Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032)
4.4 Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032)
4.5 South America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032)
4.6 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032)
5 MARKET SEGMENT BY CONCENTRATION
5.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2032)
5.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Concentration (2021-2032)
5.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2032)
6.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Application (2021-2032)
6.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2032)
7.2 North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2032)
7.3 North America Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country
7.3.1 North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2032)
7.3.2 North America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2032)
8.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2032)
8.3 Europe Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country
8.3.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2032)
8.3.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2032)
9.2 Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Region
9.3.1 Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2032)
10.2 South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2032)
10.3 South America Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country
10.3.1 South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2032)
10.3.2 South America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2032)
11.2 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country
11.3.1 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
12.2 Human Immumoglobulin (PH4) for Intravenous Injection Market Restraints
12.3 Human Immumoglobulin (PH4) for Intravenous Injection Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Human Immumoglobulin (PH4) for Intravenous Injection and Key Manufacturers
13.2 Manufacturing Costs Percentage of Human Immumoglobulin (PH4) for Intravenous Injection
13.3 Human Immumoglobulin (PH4) for Intravenous Injection Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Human Immumoglobulin (PH4) for Intravenous Injection Typical Distributors
14.3 Human Immumoglobulin (PH4) for Intravenous Injection Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Concentration, (USD Million), 2021 & 2025 & 2032
Table 2. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Source Plasma Screening Standard, (USD Million), 2021 & 2025 & 2032
Table 3. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Production Process, (USD Million), 2021 & 2025 & 2032
Table 4. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Boya-Bio Basic Information, Manufacturing Base and Competitors
Table 6. Boya-Bio Major Business
Table 7. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 8. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Boya-Bio Recent Developments/Updates
Table 10. Beijing Tiantan Biological Products Basic Information, Manufacturing Base and Competitors
Table 11. Beijing Tiantan Biological Products Major Business
Table 12. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 13. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Beijing Tiantan Biological Products Recent Developments/Updates
Table 15. Guangdong Shuagnlin Bio-pharmacy Basic Information, Manufacturing Base and Competitors
Table 16. Guangdong Shuagnlin Bio-pharmacy Major Business
Table 17. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 18. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates
Table 20. Weiguang Biological Basic Information, Manufacturing Base and Competitors
Table 21. Weiguang Biological Major Business
Table 22. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 23. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Weiguang Biological Recent Developments/Updates
Table 25. Hualan Bio Basic Information, Manufacturing Base and Competitors
Table 26. Hualan Bio Major Business
Table 27. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 28. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 29. Hualan Bio Recent Developments/Updates
Table 30. CTBB Basic Information, Manufacturing Base and Competitors
Table 31. CTBB Major Business
Table 32. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 33. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 34. CTBB Recent Developments/Updates
Table 35. Sinopharm Basic Information, Manufacturing Base and Competitors
Table 36. Sinopharm Major Business
Table 37. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 38. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 39. Sinopharm Recent Developments/Updates
Table 40. Nanyue Biopharming Basic Information, Manufacturing Base and Competitors
Table 41. Nanyue Biopharming Major Business
Table 42. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 43. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 44. Nanyue Biopharming Recent Developments/Updates
Table 45. Shanghai RAAS Basic Information, Manufacturing Base and Competitors
Table 46. Shanghai RAAS Major Business
Table 47. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 48. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 49. Shanghai RAAS Recent Developments/Updates
Table 50. ADMA Biologics Basic Information, Manufacturing Base and Competitors
Table 51. ADMA Biologics Major Business
Table 52. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 53. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 54. ADMA Biologics Recent Developments/Updates
Table 55. Grand Shuyang Basic Information, Manufacturing Base and Competitors
Table 56. Grand Shuyang Major Business
Table 57. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 58. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 59. Grand Shuyang Recent Developments/Updates
Table 60. PAFC Basic Information, Manufacturing Base and Competitors
Table 61. PAFC Major Business
Table 62. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 63. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 64. PAFC Recent Developments/Updates
Table 65. Weiguang Biological Products Basic Information, Manufacturing Base and Competitors
Table 66. Weiguang Biological Products Major Business
Table 67. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 68. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 69. Weiguang Biological Products Recent Developments/Updates
Table 70. Beijing Bohui Innovation Biotechnology Basic Information, Manufacturing Base and Competitors
Table 71. Beijing Bohui Innovation Biotechnology Major Business
Table 72. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 73. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 74. Beijing Bohui Innovation Biotechnology Recent Developments/Updates
Table 75. CSL Behring Basic Information, Manufacturing Base and Competitors
Table 76. CSL Behring Major Business
Table 77. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 78. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. CSL Behring Recent Developments/Updates
Table 80. Takeda Basic Information, Manufacturing Base and Competitors
Table 81. Takeda Major Business
Table 82. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 83. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 84. Takeda Recent Developments/Updates
Table 85. Grifols Basic Information, Manufacturing Base and Competitors
Table 86. Grifols Major Business
Table 87. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 88. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 89. Grifols Recent Developments/Updates
Table 90. Octapharma Basic Information, Manufacturing Base and Competitors
Table 91. Octapharma Major Business
Table 92. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 93. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 94. Octapharma Recent Developments/Updates
Table 95. Bio Products Laboratory Basic Information, Manufacturing Base and Competitors
Table 96. Bio Products Laboratory Major Business
Table 97. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 98. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 99. Bio Products Laboratory Recent Developments/Updates
Table 100. Kedrion Basic Information, Manufacturing Base and Competitors
Table 101. Kedrion Major Business
Table 102. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 103. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 104. Kedrion Recent Developments/Updates
Table 105. LFB Basic Information, Manufacturing Base and Competitors
Table 106. LFB Major Business
Table 107. LFB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 108. LFB Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. LFB Recent Developments/Updates
Table 110. GC Biopharma Basic Information, Manufacturing Base and Competitors
Table 111. GC Biopharma Major Business
Table 112. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 113. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 114. GC Biopharma Recent Developments/Updates
Table 115. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Manufacturer (2021-2026) & (Tons)
Table 116. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Manufacturer (2021-2026) & (USD Million)
Table 117. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Manufacturer (2021-2026) & (US$/g)
Table 118. Market Position of Manufacturers in Human Immumoglobulin (PH4) for Intravenous Injection, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 119. Head Office and Human Immumoglobulin (PH4) for Intravenous Injection Production Site of Key Manufacturer
Table 120. Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Type Footprint
Table 121. Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Application Footprint
Table 122. Human Immumoglobulin (PH4) for Intravenous Injection New Market Entrants and Barriers to Market Entry
Table 123. Human Immumoglobulin (PH4) for Intravenous Injection Mergers, Acquisition, Agreements, and Collaborations
Table 124. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 125. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Region (2021-2026) & (Tons)
Table 126. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Region (2027-2032) & (Tons)
Table 127. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2021-2026) & (USD Million)
Table 128. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2027-2032) & (USD Million)
Table 129. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2021-2026) & (US$/g)
Table 130. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2027-2032) & (US$/g)
Table 131. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2026) & (Tons)
Table 132. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2027-2032) & (Tons)
Table 133. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Concentration (2021-2026) & (USD Million)
Table 134. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Concentration (2027-2032) & (USD Million)
Table 135. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2026) & (US$/g)
Table 136. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2027-2032) & (US$/g)
Table 137. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2026) & (Tons)
Table 138. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2027-2032) & (Tons)
Table 139. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Application (2021-2026) & (USD Million)
Table 140. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Application (2027-2032) & (USD Million)
Table 141. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2026) & (US$/g)
Table 142. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2027-2032) & (US$/g)
Table 143. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2026) & (Tons)
Table 144. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2027-2032) & (Tons)
Table 145. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2026) & (Tons)
Table 146. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2027-2032) & (Tons)
Table 147. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2026) & (Tons)
Table 148. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2027-2032) & (Tons)
Table 149. North America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2026) & (USD Million)
Table 150. North America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2027-2032) & (USD Million)
Table 151. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2026) & (Tons)
Table 152. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2027-2032) & (Tons)
Table 153. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2026) & (Tons)
Table 154. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2027-2032) & (Tons)
Table 155. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2026) & (Tons)
Table 156. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2027-2032) & (Tons)
Table 157. Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2026) & (USD Million)
Table 158. Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2027-2032) & (USD Million)
Table 159. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2026) & (Tons)
Table 160. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2027-2032) & (Tons)
Table 161. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2026) & (Tons)
Table 162. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2027-2032) & (Tons)
Table 163. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Region (2021-2026) & (Tons)
Table 164. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Region (2027-2032) & (Tons)
Table 165. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2021-2026) & (USD Million)
Table 166. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2027-2032) & (USD Million)
Table 167. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2026) & (Tons)
Table 168. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2027-2032) & (Tons)
Table 169. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2026) & (Tons)
Table 170. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2027-2032) & (Tons)
Table 171. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2026) & (Tons)
Table 172. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2027-2032) & (Tons)
Table 173. South America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2026) & (USD Million)
Table 174. South America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2027-2032) & (USD Million)
Table 175. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2026) & (Tons)
Table 176. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2027-2032) & (Tons)
Table 177. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2026) & (Tons)
Table 178. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2027-2032) & (Tons)
Table 179. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2026) & (Tons)
Table 180. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2027-2032) & (Tons)
Table 181. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2026) & (USD Million)
Table 182. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2027-2032) & (USD Million)
Table 183. Human Immumoglobulin (PH4) for Intravenous Injection Raw Material
Table 184. Key Manufacturers of Human Immumoglobulin (PH4) for Intravenous Injection Raw Materials
Table 185. Human Immumoglobulin (PH4) for Intravenous Injection Typical Distributors
Table 186. Human Immumoglobulin (PH4) for Intravenous Injection Typical Customers
Table 1. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Concentration, (USD Million), 2021 & 2025 & 2032
Table 2. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Source Plasma Screening Standard, (USD Million), 2021 & 2025 & 2032
Table 3. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Production Process, (USD Million), 2021 & 2025 & 2032
Table 4. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Boya-Bio Basic Information, Manufacturing Base and Competitors
Table 6. Boya-Bio Major Business
Table 7. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 8. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Boya-Bio Recent Developments/Updates
Table 10. Beijing Tiantan Biological Products Basic Information, Manufacturing Base and Competitors
Table 11. Beijing Tiantan Biological Products Major Business
Table 12. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 13. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Beijing Tiantan Biological Products Recent Developments/Updates
Table 15. Guangdong Shuagnlin Bio-pharmacy Basic Information, Manufacturing Base and Competitors
Table 16. Guangdong Shuagnlin Bio-pharmacy Major Business
Table 17. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 18. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates
Table 20. Weiguang Biological Basic Information, Manufacturing Base and Competitors
Table 21. Weiguang Biological Major Business
Table 22. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 23. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Weiguang Biological Recent Developments/Updates
Table 25. Hualan Bio Basic Information, Manufacturing Base and Competitors
Table 26. Hualan Bio Major Business
Table 27. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 28. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 29. Hualan Bio Recent Developments/Updates
Table 30. CTBB Basic Information, Manufacturing Base and Competitors
Table 31. CTBB Major Business
Table 32. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 33. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 34. CTBB Recent Developments/Updates
Table 35. Sinopharm Basic Information, Manufacturing Base and Competitors
Table 36. Sinopharm Major Business
Table 37. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 38. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 39. Sinopharm Recent Developments/Updates
Table 40. Nanyue Biopharming Basic Information, Manufacturing Base and Competitors
Table 41. Nanyue Biopharming Major Business
Table 42. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 43. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 44. Nanyue Biopharming Recent Developments/Updates
Table 45. Shanghai RAAS Basic Information, Manufacturing Base and Competitors
Table 46. Shanghai RAAS Major Business
Table 47. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 48. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 49. Shanghai RAAS Recent Developments/Updates
Table 50. ADMA Biologics Basic Information, Manufacturing Base and Competitors
Table 51. ADMA Biologics Major Business
Table 52. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 53. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 54. ADMA Biologics Recent Developments/Updates
Table 55. Grand Shuyang Basic Information, Manufacturing Base and Competitors
Table 56. Grand Shuyang Major Business
Table 57. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 58. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 59. Grand Shuyang Recent Developments/Updates
Table 60. PAFC Basic Information, Manufacturing Base and Competitors
Table 61. PAFC Major Business
Table 62. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 63. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 64. PAFC Recent Developments/Updates
Table 65. Weiguang Biological Products Basic Information, Manufacturing Base and Competitors
Table 66. Weiguang Biological Products Major Business
Table 67. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 68. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 69. Weiguang Biological Products Recent Developments/Updates
Table 70. Beijing Bohui Innovation Biotechnology Basic Information, Manufacturing Base and Competitors
Table 71. Beijing Bohui Innovation Biotechnology Major Business
Table 72. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 73. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 74. Beijing Bohui Innovation Biotechnology Recent Developments/Updates
Table 75. CSL Behring Basic Information, Manufacturing Base and Competitors
Table 76. CSL Behring Major Business
Table 77. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 78. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. CSL Behring Recent Developments/Updates
Table 80. Takeda Basic Information, Manufacturing Base and Competitors
Table 81. Takeda Major Business
Table 82. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 83. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 84. Takeda Recent Developments/Updates
Table 85. Grifols Basic Information, Manufacturing Base and Competitors
Table 86. Grifols Major Business
Table 87. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 88. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 89. Grifols Recent Developments/Updates
Table 90. Octapharma Basic Information, Manufacturing Base and Competitors
Table 91. Octapharma Major Business
Table 92. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 93. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 94. Octapharma Recent Developments/Updates
Table 95. Bio Products Laboratory Basic Information, Manufacturing Base and Competitors
Table 96. Bio Products Laboratory Major Business
Table 97. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 98. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 99. Bio Products Laboratory Recent Developments/Updates
Table 100. Kedrion Basic Information, Manufacturing Base and Competitors
Table 101. Kedrion Major Business
Table 102. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 103. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 104. Kedrion Recent Developments/Updates
Table 105. LFB Basic Information, Manufacturing Base and Competitors
Table 106. LFB Major Business
Table 107. LFB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 108. LFB Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. LFB Recent Developments/Updates
Table 110. GC Biopharma Basic Information, Manufacturing Base and Competitors
Table 111. GC Biopharma Major Business
Table 112. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
Table 113. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (Tons), Average Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 114. GC Biopharma Recent Developments/Updates
Table 115. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Manufacturer (2021-2026) & (Tons)
Table 116. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Manufacturer (2021-2026) & (USD Million)
Table 117. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Manufacturer (2021-2026) & (US$/g)
Table 118. Market Position of Manufacturers in Human Immumoglobulin (PH4) for Intravenous Injection, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 119. Head Office and Human Immumoglobulin (PH4) for Intravenous Injection Production Site of Key Manufacturer
Table 120. Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Type Footprint
Table 121. Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Application Footprint
Table 122. Human Immumoglobulin (PH4) for Intravenous Injection New Market Entrants and Barriers to Market Entry
Table 123. Human Immumoglobulin (PH4) for Intravenous Injection Mergers, Acquisition, Agreements, and Collaborations
Table 124. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 125. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Region (2021-2026) & (Tons)
Table 126. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Region (2027-2032) & (Tons)
Table 127. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2021-2026) & (USD Million)
Table 128. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2027-2032) & (USD Million)
Table 129. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2021-2026) & (US$/g)
Table 130. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2027-2032) & (US$/g)
Table 131. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2026) & (Tons)
Table 132. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2027-2032) & (Tons)
Table 133. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Concentration (2021-2026) & (USD Million)
Table 134. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Concentration (2027-2032) & (USD Million)
Table 135. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2026) & (US$/g)
Table 136. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2027-2032) & (US$/g)
Table 137. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2026) & (Tons)
Table 138. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2027-2032) & (Tons)
Table 139. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Application (2021-2026) & (USD Million)
Table 140. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Application (2027-2032) & (USD Million)
Table 141. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2026) & (US$/g)
Table 142. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2027-2032) & (US$/g)
Table 143. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2026) & (Tons)
Table 144. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2027-2032) & (Tons)
Table 145. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2026) & (Tons)
Table 146. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2027-2032) & (Tons)
Table 147. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2026) & (Tons)
Table 148. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2027-2032) & (Tons)
Table 149. North America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2026) & (USD Million)
Table 150. North America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2027-2032) & (USD Million)
Table 151. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2026) & (Tons)
Table 152. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2027-2032) & (Tons)
Table 153. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2026) & (Tons)
Table 154. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2027-2032) & (Tons)
Table 155. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2026) & (Tons)
Table 156. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2027-2032) & (Tons)
Table 157. Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2026) & (USD Million)
Table 158. Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2027-2032) & (USD Million)
Table 159. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2026) & (Tons)
Table 160. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2027-2032) & (Tons)
Table 161. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2026) & (Tons)
Table 162. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2027-2032) & (Tons)
Table 163. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Region (2021-2026) & (Tons)
Table 164. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Region (2027-2032) & (Tons)
Table 165. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2021-2026) & (USD Million)
Table 166. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Region (2027-2032) & (USD Million)
Table 167. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2026) & (Tons)
Table 168. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2027-2032) & (Tons)
Table 169. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2026) & (Tons)
Table 170. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2027-2032) & (Tons)
Table 171. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2026) & (Tons)
Table 172. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2027-2032) & (Tons)
Table 173. South America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2026) & (USD Million)
Table 174. South America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2027-2032) & (USD Million)
Table 175. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2021-2026) & (Tons)
Table 176. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Concentration (2027-2032) & (Tons)
Table 177. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2021-2026) & (Tons)
Table 178. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Application (2027-2032) & (Tons)
Table 179. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2021-2026) & (Tons)
Table 180. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity by Country (2027-2032) & (Tons)
Table 181. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2021-2026) & (USD Million)
Table 182. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Country (2027-2032) & (USD Million)
Table 183. Human Immumoglobulin (PH4) for Intravenous Injection Raw Material
Table 184. Key Manufacturers of Human Immumoglobulin (PH4) for Intravenous Injection Raw Materials
Table 185. Human Immumoglobulin (PH4) for Intravenous Injection Typical Distributors
Table 186. Human Immumoglobulin (PH4) for Intravenous Injection Typical Customers
LIST OF FIGURES
Figure 1. Human Immumoglobulin (PH4) for Intravenous Injection Picture
Figure 2. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Concentration, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Concentration in 2025
Figure 4. 5% Examples
Figure 5. 10% Examples
Figure 6. 20% Examples
Figure 7. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Source Plasma Screening Standard, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Source Plasma Screening Standard in 2025
Figure 9. Standard-Qualified Plasma Examples
Figure 10. High-Safety Plasma Examples
Figure 11. Special-Indication Examples
Figure 12. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Production Process, (USD Million), 2021 & 2025 & 2032
Figure 13. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Production Process in 2025
Figure 14. Cohn-Fractionation Examples
Figure 15. Chromatography-Purified Examples
Figure 16. Ultrafiltration-Refined Examples
Figure 17. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 18. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application in 2025
Figure 19. Immunodeficiency Disease Examples
Figure 20. Autoimmune Disease Examples
Figure 21. Severe Infectious Disease Examples
Figure 22. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 23. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 24. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (2021-2032) & (Tons)
Figure 25. Global Human Immumoglobulin (PH4) for Intravenous Injection Price (2021-2032) & (US$/g)
Figure 26. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Manufacturer in 2025
Figure 27. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Manufacturer in 2025
Figure 28. Producer Shipments of Human Immumoglobulin (PH4) for Intravenous Injection by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 29. Top 3 Human Immumoglobulin (PH4) for Intravenous Injection Manufacturer (Revenue) Market Share in 2025
Figure 30. Top 6 Human Immumoglobulin (PH4) for Intravenous Injection Manufacturer (Revenue) Market Share in 2025
Figure 31. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Region (2021-2032)
Figure 32. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Region (2021-2032)
Figure 33. North America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 34. Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 35. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 36. South America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 37. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 38. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Concentration (2021-2032)
Figure 39. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Concentration (2021-2032)
Figure 40. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2032) & (US$/g)
Figure 41. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Application (2021-2032)
Figure 42. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2021-2032)
Figure 43. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2032) & (US$/g)
Figure 44. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Concentration (2021-2032)
Figure 45. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Application (2021-2032)
Figure 46. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Country (2021-2032)
Figure 47. North America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Country (2021-2032)
Figure 48. United States Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 49. Canada Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 50. Mexico Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 51. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Concentration (2021-2032)
Figure 52. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Application (2021-2032)
Figure 53. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Country (2021-2032)
Figure 54. Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Country (2021-2032)
Figure 55. Germany Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 56. France Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 57. United Kingdom Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 58. Russia Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 59. Italy Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 60. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Concentration (2021-2032)
Figure 61. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Application (2021-2032)
Figure 62. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Region (2021-2032)
Figure 63. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Region (2021-2032)
Figure 64. China Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 65. Japan Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 66. South Korea Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 67. India Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 68. Southeast Asia Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 69. Australia Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 70. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Concentration (2021-2032)
Figure 71. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Application (2021-2032)
Figure 72. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Country (2021-2032)
Figure 73. South America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Country (2021-2032)
Figure 74. Brazil Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 75. Argentina Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 76. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Concentration (2021-2032)
Figure 77. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Application (2021-2032)
Figure 78. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Country (2021-2032)
Figure 79. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Country (2021-2032)
Figure 80. Turkey Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 81. Egypt Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 82. Saudi Arabia Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 83. South Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 84. Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
Figure 85. Human Immumoglobulin (PH4) for Intravenous Injection Market Restraints
Figure 86. Human Immumoglobulin (PH4) for Intravenous Injection Market Trends
Figure 87. Porters Five Forces Analysis
Figure 88. Manufacturing Cost Structure Analysis of Human Immumoglobulin (PH4) for Intravenous Injection in 2025
Figure 89. Manufacturing Process Analysis of Human Immumoglobulin (PH4) for Intravenous Injection
Figure 90. Human Immumoglobulin (PH4) for Intravenous Injection Industrial Chain
Figure 91. Sales Channel: Direct to End-User vs Distributors
Figure 92. Direct Channel Pros & Cons
Figure 93. Indirect Channel Pros & Cons
Figure 94. Methodology
Figure 95. Research Process and Data Source
Figure 1. Human Immumoglobulin (PH4) for Intravenous Injection Picture
Figure 2. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Concentration, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Concentration in 2025
Figure 4. 5% Examples
Figure 5. 10% Examples
Figure 6. 20% Examples
Figure 7. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Source Plasma Screening Standard, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Source Plasma Screening Standard in 2025
Figure 9. Standard-Qualified Plasma Examples
Figure 10. High-Safety Plasma Examples
Figure 11. Special-Indication Examples
Figure 12. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Production Process, (USD Million), 2021 & 2025 & 2032
Figure 13. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Production Process in 2025
Figure 14. Cohn-Fractionation Examples
Figure 15. Chromatography-Purified Examples
Figure 16. Ultrafiltration-Refined Examples
Figure 17. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 18. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application in 2025
Figure 19. Immunodeficiency Disease Examples
Figure 20. Autoimmune Disease Examples
Figure 21. Severe Infectious Disease Examples
Figure 22. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 23. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 24. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity (2021-2032) & (Tons)
Figure 25. Global Human Immumoglobulin (PH4) for Intravenous Injection Price (2021-2032) & (US$/g)
Figure 26. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Manufacturer in 2025
Figure 27. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Manufacturer in 2025
Figure 28. Producer Shipments of Human Immumoglobulin (PH4) for Intravenous Injection by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 29. Top 3 Human Immumoglobulin (PH4) for Intravenous Injection Manufacturer (Revenue) Market Share in 2025
Figure 30. Top 6 Human Immumoglobulin (PH4) for Intravenous Injection Manufacturer (Revenue) Market Share in 2025
Figure 31. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Region (2021-2032)
Figure 32. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Region (2021-2032)
Figure 33. North America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 34. Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 35. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 36. South America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 37. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 38. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Concentration (2021-2032)
Figure 39. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Concentration (2021-2032)
Figure 40. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2032) & (US$/g)
Figure 41. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Application (2021-2032)
Figure 42. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2021-2032)
Figure 43. Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2032) & (US$/g)
Figure 44. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Concentration (2021-2032)
Figure 45. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Application (2021-2032)
Figure 46. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Country (2021-2032)
Figure 47. North America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Country (2021-2032)
Figure 48. United States Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 49. Canada Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 50. Mexico Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 51. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Concentration (2021-2032)
Figure 52. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Application (2021-2032)
Figure 53. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Country (2021-2032)
Figure 54. Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Country (2021-2032)
Figure 55. Germany Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 56. France Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 57. United Kingdom Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 58. Russia Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 59. Italy Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 60. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Concentration (2021-2032)
Figure 61. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Application (2021-2032)
Figure 62. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Region (2021-2032)
Figure 63. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Region (2021-2032)
Figure 64. China Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 65. Japan Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 66. South Korea Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 67. India Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 68. Southeast Asia Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 69. Australia Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 70. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Concentration (2021-2032)
Figure 71. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Application (2021-2032)
Figure 72. South America Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Country (2021-2032)
Figure 73. South America Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Country (2021-2032)
Figure 74. Brazil Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 75. Argentina Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 76. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Concentration (2021-2032)
Figure 77. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Application (2021-2032)
Figure 78. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Quantity Market Share by Country (2021-2032)
Figure 79. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value Market Share by Country (2021-2032)
Figure 80. Turkey Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 81. Egypt Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 82. Saudi Arabia Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 83. South Africa Human Immumoglobulin (PH4) for Intravenous Injection Consumption Value (2021-2032) & (USD Million)
Figure 84. Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
Figure 85. Human Immumoglobulin (PH4) for Intravenous Injection Market Restraints
Figure 86. Human Immumoglobulin (PH4) for Intravenous Injection Market Trends
Figure 87. Porters Five Forces Analysis
Figure 88. Manufacturing Cost Structure Analysis of Human Immumoglobulin (PH4) for Intravenous Injection in 2025
Figure 89. Manufacturing Process Analysis of Human Immumoglobulin (PH4) for Intravenous Injection
Figure 90. Human Immumoglobulin (PH4) for Intravenous Injection Industrial Chain
Figure 91. Sales Channel: Direct to End-User vs Distributors
Figure 92. Direct Channel Pros & Cons
Figure 93. Indirect Channel Pros & Cons
Figure 94. Methodology
Figure 95. Research Process and Data Source
